Research shows bulevirtide and peginterferon alfa-2a best treatment for chronic hepatitis D

The combination of bulevirtide plus peginterferon alfa-2a is superior to bulevirtide monotherapy for achieving undetectable hepatitis D virus (HDV) RNA level at 24 weeks after the end of treatment in patients with chronic hepatitis D, according to a study published online June 6 in the New England Journal of Medicine to coincide with the annual congress of the European Association for the Study of the Liver, held from June 5 to 8 in Milan.

This article was originally published on

You may also be interested in:

Read More:

Lawyers Lookup